Table 2 Treatment-emergent adverse events

From: Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

Patients (N = 24)

Grade 1–2

Grade 3–4

Neutropenia

8 (33)

14 (58)

ALT elevation

7 (29)

4 (17)

AST elevation

6 (25)

3 (12.5)

Infection

8 (33)

3 (12.5)

Anemia

18 (75)

2 (8)

Skin rash

10 (42)

2 (8)

Fatigue

18 (75)

1 (4)

Nausea

6 (25)

1 (4)

Infusion-related reaction

5 (21)

1 (4)

Peripheral neuropathy

4 (17)

1 (4)

Lymphopenia

3 (12.5)

1 (4)

Atrial fibrillation

0 (0)

1 (4)

Thrombocytopenia

16 (67)

0 (0)

Headache

14 (58)

0 (0)

Diarrhea

10 (42)

0 (0)

Pruritus

7 (29)

0 (0)

Arthralgia

7 (29)

0 (0)

Bruising

6 (25)

0 (0)

Myalgia

6 (25)

0 (0)

Dizziness

5 (21)

0 (0)

Dry skin

4 (17)

0 (0)

Sinus bradycardia

3 (12.5)

0 (0)

Dysgeusia

2 (4)

0 (0)

Back to article page